Pfizer Inc. (PFE)
28.90
+0.07
(+0.24%)
USD |
NYSE |
Nov 13, 16:00
28.86
-0.04
(-0.16%)
After-Hours: 17:03
Pfizer Enterprise Value : 213.03B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 213.03B |
| November 11, 2026 | 216.56B |
| November 10, 2026 | 216.05B |
| November 09, 2026 | 215.31B |
| November 06, 2026 | 216.22B |
| November 05, 2026 | 219.01B |
| November 04, 2026 | 224.20B |
| November 03, 2026 | 219.70B |
| November 02, 2026 | 223.52B |
| October 30, 2026 | 222.66B |
| October 29, 2026 | 219.41B |
| October 28, 2026 | 216.56B |
| October 27, 2026 | 218.56B |
| October 26, 2026 | 218.50B |
| October 23, 2026 | 219.87B |
| October 22, 2026 | 222.09B |
| October 21, 2026 | 218.84B |
| October 20, 2026 | 220.32B |
| October 19, 2026 | 216.51B |
| October 16, 2026 | 217.30B |
| October 15, 2026 | 216.51B |
| October 14, 2026 | 215.20B |
| October 13, 2026 | 210.41B |
| October 12, 2026 | 210.58B |
| October 09, 2026 | 209.89B |
| Date | Value |
|---|---|
| October 08, 2026 | 207.27B |
| October 07, 2026 | 208.30B |
| October 06, 2026 | 205.45B |
| October 05, 2026 | 204.94B |
| October 02, 2026 | 207.16B |
| October 01, 2026 | 208.98B |
| September 30, 2026 | 211.26B |
| September 29, 2026 | 215.47B |
| September 28, 2026 | 215.47B |
| September 25, 2026 | 215.19B |
| September 24, 2026 | 213.71B |
| September 23, 2026 | 212.39B |
| September 22, 2026 | 210.97B |
| September 21, 2026 | 209.89B |
| September 18, 2026 | 209.43B |
| September 17, 2026 | 209.32B |
| September 16, 2026 | 208.29B |
| September 15, 2026 | 208.80B |
| September 14, 2026 | 209.77B |
| September 11, 2026 | 209.77B |
| September 10, 2026 | 209.37B |
| September 09, 2026 | 210.12B |
| September 08, 2026 | 210.17B |
| September 04, 2026 | 213.93B |
| September 03, 2026 | 215.99B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Johnson & Johnson | 709.89B |
| Eli Lilly & Co. | 1.388T |
| Merck & Co., Inc. | 406.57B |
| Bristol Myers Squibb Co. | 159.61B |
| Abbott Laboratories | 213.21B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.251B |
| Revenue (Quarterly) | 16.58B |
| Total Expenses (Quarterly) | 13.34B |
| EPS Diluted (Quarterly) | 0.5637 |
| Gross Profit Margin (Quarterly) | 68.17% |
| Profit Margin (Quarterly) | 19.60% |
| Earnings Yield | 2.42% |
| Operating Earnings Yield | 9.99% |
| Normalized Earnings Yield | 7.853 |